FI970100L - Muunnetun superantigeenin ja kohdetta etsivän yhdisteen välinen konjugaatti ja konjugaatin käyttö - Google Patents

Muunnetun superantigeenin ja kohdetta etsivän yhdisteen välinen konjugaatti ja konjugaatin käyttö Download PDF

Info

Publication number
FI970100L
FI970100L FI970100A FI970100A FI970100L FI 970100 L FI970100 L FI 970100L FI 970100 A FI970100 A FI 970100A FI 970100 A FI970100 A FI 970100A FI 970100 L FI970100 L FI 970100L
Authority
FI
Finland
Prior art keywords
conjugate
target
modified superantigen
seeking compound
seeking
Prior art date
Application number
FI970100A
Other languages
English (en)
Swedish (sv)
Other versions
FI970100A0 (fi
FI118150B (fi
Inventor
Lars Abrahamsen
Per Bjoerk
Mikael Dohlsten
Terje Kalland
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of FI970100A0 publication Critical patent/FI970100A0/fi
Publication of FI970100L publication Critical patent/FI970100L/fi
Application granted granted Critical
Publication of FI118150B publication Critical patent/FI118150B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI970100A 1994-07-11 1997-01-10 Muunnetun superantigeenin ja kohdetta etsivän yhdisteen välinen konjugaatti ja konjugaatin käyttö FI118150B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9402430 1994-07-11
SE9402430A SE9402430L (sv) 1994-07-11 1994-07-11 Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9500681 1995-06-07
PCT/SE1995/000681 WO1996001650A1 (en) 1994-07-11 1995-06-07 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate

Publications (3)

Publication Number Publication Date
FI970100A0 FI970100A0 (fi) 1997-01-10
FI970100L true FI970100L (fi) 1997-01-10
FI118150B FI118150B (fi) 2007-07-31

Family

ID=20394684

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970100A FI118150B (fi) 1994-07-11 1997-01-10 Muunnetun superantigeenin ja kohdetta etsivän yhdisteen välinen konjugaatti ja konjugaatin käyttö

Country Status (26)

Country Link
US (3) US7226601B1 (fi)
EP (1) EP0766566B1 (fi)
JP (1) JP4175489B2 (fi)
KR (1) KR100377506B1 (fi)
CN (1) CN1089606C (fi)
AT (1) ATE200626T1 (fi)
AU (1) AU699147B2 (fi)
CA (1) CA2194673C (fi)
DE (1) DE69520739T2 (fi)
DK (1) DK0766566T3 (fi)
ES (1) ES2158950T3 (fi)
FI (1) FI118150B (fi)
GR (1) GR3036187T3 (fi)
HU (1) HU221254B1 (fi)
IL (1) IL114445A (fi)
MY (1) MY112916A (fi)
NO (1) NO320151B1 (fi)
NZ (1) NZ289951A (fi)
PL (1) PL180747B1 (fi)
PT (1) PT766566E (fi)
RU (1) RU2183215C2 (fi)
SE (1) SE9402430L (fi)
TW (1) TW413636B (fi)
UA (1) UA73067C2 (fi)
WO (1) WO1996001650A1 (fi)
ZA (1) ZA955746B (fi)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
BR9815493A (pt) * 1997-07-21 2000-10-31 Pharmacia & Upjohn Ab Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes
DE19827837A1 (de) * 1998-06-23 1999-12-30 Ernst Gleichmann Universell an Haupthistokompatibilitätskomplexmoleküle der Klasse II bindende Peptide zur prädiktiven Testung, Diagnostik, Prophylaxe und Therapie von Sensibilisierungen gegen Chemikalen
US7491402B2 (en) 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118155D0 (en) * 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
NZ519371A (en) 2002-06-04 2004-11-26 Auckland Uniservices Ltd Immunomodulatory constructs and their uses
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
EP1812574A2 (en) * 2004-11-18 2007-08-01 Avidex Limited Soluble bifunctional proteins
EP2500352A1 (en) * 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN102516392B (zh) * 2011-11-25 2014-05-28 孙嘉琳 一种癌靶向超抗原融合蛋白及制备方法及用途
WO2014025199A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
EP3411409B1 (en) 2016-01-10 2025-10-08 Neotx Therapeutics Ltd. Anti pd-1/anti-pd-l1 antibodies for enhancing the potency of superantigen mediated cancer immunotherapy
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
US20210299268A1 (en) * 2018-07-09 2021-09-30 Synthis Therapeutics, Inc. Antibody-alk5 inhibitor conjugates and their uses
CN114025791A (zh) 2019-05-15 2022-02-08 尼奥克斯医疗有限公司 癌症治疗
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627644A (en) 1968-03-01 1971-12-14 Hajime Okamoto Process for the cultivation of hemolytic streptococci
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4268434A (en) 1979-01-09 1981-05-19 Higerd Thomas B Immunosuppressive extracellular product from oral bacteria
SU1304736A3 (ru) * 1981-04-14 1987-04-15 Др.Мадаус Унд Ко (Фирма) Способ получени противоопухолевого средства
US5091091A (en) 1981-11-06 1992-02-25 Terman David S Protein A perfusion and post perfusion drug infusion
US4699783A (en) 1983-03-11 1987-10-13 Terman David S Products and methods for treatment of cancer
US4681870A (en) 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
IT1192014B (it) 1986-06-27 1988-03-31 Rubinetterie Mariani Spa Becco di erogazione per lavabo o simile apparecchio idraulico con comando del salterello
US4980160A (en) 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
DE68907388T2 (de) 1988-07-22 1994-01-05 Imre Corp Gereinigte Protein A-Zusammensetzungen und Verfahren zu ihrer Herstellung.
SE8903100D0 (sv) 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
ATE304371T1 (de) 1990-01-17 2005-09-15 David S Terman Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
ES2094231T3 (es) * 1990-07-20 1997-01-16 Pharmacia & Upjohn Ab Conjugados de anticuerpos superantigenos especificos de una diana y su preparacion.
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
US6197299B1 (en) * 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
JPH08500328A (ja) 1992-01-28 1996-01-16 ナショナル ジューイッシュ センター フォア イミュノロジィ アンド レスパラトリィ メディスン 突然変異したスーパー抗原の保護作用
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy

Also Published As

Publication number Publication date
EP0766566B1 (en) 2001-04-18
US20060062795A1 (en) 2006-03-23
NO320151B1 (no) 2005-10-31
NO970108L (no) 1997-02-20
HU221254B1 (en) 2002-09-28
CN1089606C (zh) 2002-08-28
PT766566E (pt) 2001-09-28
GR3036187T3 (en) 2001-10-31
JPH11500407A (ja) 1999-01-12
IL114445A (en) 1999-09-22
US7226601B1 (en) 2007-06-05
AU2994095A (en) 1996-02-09
DK0766566T3 (da) 2001-08-13
HUT77257A (hu) 1998-03-02
JP4175489B2 (ja) 2008-11-05
CN1152877A (zh) 1997-06-25
HK1012226A1 (en) 1999-07-30
PL180747B1 (pl) 2001-04-30
ZA955746B (en) 1996-02-20
IL114445A0 (en) 1995-11-27
MY112916A (en) 2001-10-31
PL318162A1 (en) 1997-05-26
FI970100A0 (fi) 1997-01-10
NO970108D0 (no) 1997-01-10
EP0766566A1 (en) 1997-04-09
CA2194673C (en) 2009-08-04
ATE200626T1 (de) 2001-05-15
NZ289951A (en) 1998-12-23
CA2194673A1 (en) 1996-01-25
KR100377506B1 (ko) 2003-06-11
SE9402430L (sv) 1996-01-12
TW413636B (en) 2000-12-01
FI118150B (fi) 2007-07-31
US20050260215A1 (en) 2005-11-24
SE9402430D0 (sv) 1994-07-11
RU2183215C2 (ru) 2002-06-10
AU699147B2 (en) 1998-11-26
WO1996001650A1 (en) 1996-01-25
DE69520739D1 (de) 2001-05-23
ES2158950T3 (es) 2001-09-16
DE69520739T2 (de) 2001-09-20
UA73067C2 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
FI970100L (fi) Muunnetun superantigeenin ja kohdetta etsivän yhdisteen välinen konjugaatti ja konjugaatin käyttö
FI955051A0 (fi) Heterosyklisiä yhdisteitä ja niiden valmistus ja käyttö
FI963238A7 (fi) Heteroaromaattisia oksatsoli yhdisteitä ja niiden käyttö
FI945281A7 (fi) Heterosykliset yhdisteet, niiden valmistus ja käyttö
FI944310A7 (fi) Heteroaryyliamino- ja heteroaryylisuolfonamidosubstituoituja 3-bentsyyliaminometyylipiperidiinejä ja vastaavia yhdisteitä
FI953666A7 (fi) Hetersykliset yhdisteet ja niiden valmistus ja käyttö
FI954131L (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
FI954130L (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
FI942881A7 (fi) 2-piperatsinoniyhdisteet ja niiden käyttö
FI972245A0 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
BR9502407A (pt) Composição lubrificante e concetrado
FI964031L (fi) Bentsamidijohdannainen, mainittua johdannaista sisältävät koostumukset ja sen käyttö
FI964482A7 (fi) Amidijohdannaisia ja niiden käyttö lääkkeenä
FI970997L (fi) Bentsosykloalkeeniyhdisteet, niiden valmistus ja käyttö
FI964267A7 (fi) Porfosyaniini ja CNC-laajennetut porfyriinit
BR9509688A (pt) Composto e composição farmacêutica
FI960491A7 (fi) Elektrodialysaattorin päätykotelo, tällaisella kotelolla varustettu elektrodialysaattori ja elektrodialysaattorin käyttäminen
FI954229L (fi) Heterosykliset yhdisteet, niiden käyttö ja valmistus
ID16394A (id) Popok sekali pakai dari jenis celana
FI963130L (fi) Heterosykliset yhdisteet sekä niiden valmistus ja käyttö
FI911644A7 (fi) Terapeuttinen yhdiste ja koostumus
FI971317A7 (fi) Uusia heterosyklisiä, substituoituja imidatsolokinoksalinoneja, niiden valmistus ja käyttö
FI965172L (fi) Uusia amido-kinoksaliinidioneja, niiden valmistus ja käyttö
FI940454A7 (fi) Puun ja putken välinen liitos
BR9505130A (pt) Composto e composiçao farmacêutica

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118150

Country of ref document: FI

MM Patent lapsed